Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;24(2):e13789.
doi: 10.1111/tid.13789. Epub 2022 Feb 1.

Evaluation of cytomegalovirus "Blips" in high-risk kidney/kidney-pancreas transplant recipients

Alexandra T Payne  1 , Brian K Lindner  2 , Alexander J Gilbert  3 , Rebecca N Kumar  4 , Beje S Thomas  3 , Joseph G Timpone  4
Affiliations

Evaluation of cytomegalovirus "Blips" in high-risk kidney/kidney-pancreas transplant recipients

Alexandra T Payne et al. Transpl Infect Dis. 2022 Apr.

Abstract

Background: Cytomegalovirus (CMV) is a significant cause of morbidity and mortality after solid organ transplantation. While guidelines suggest using highly sensitive QNAT assays for CMV detection, there is no defined viral load to guide initiation of preemptive therapy. This study evaluates the progression to quantifiable CMV (DNAemia) following a CMV "blip" in high-risk (D+/R) kidney/kidney-pancreas (KP) transplant recipients.

Methods: This is a single center, retrospective study. A CMV "blip" was defined as the first positive QNAT assay below the level of quantification (<1.37 × 102 IU/ml or <200 viral copies). Subsequent CMV QNAT assays were followed to assess the progression from blip to CMV DNAemia for 1 year following transplant.

Results: A total of 134 patients were included in the study. Fifty-three (39.6%) patients had their first positive CMV QNAT value below the level of quantification, a "CMV blip." Of these 53 patients, 69.8% (n = 37) progressed to DNAemia while 30.2% (n = 16) did not. The median time from transplant to the first CMV blip was 68 (46-97) days and most patients with viral blips (71.1%) were on prophylaxis. No differences in patient characteristics were found among those who progressed from blip to DNAemia and those who only had a blip.

Conclusions: In CMV high-risk kidney/KP transplant recipients, CMV blips progressed to CMV DNAemia in the majority of cases. This progression typically occurred 2-3 weeks following the initial blip. CMV blips are common early posttransplant despite prophylaxis and likely represent an early marker of CMV infection.

Keywords: CMV DNAemia; cytomegalovirus; kidney transplant; kidney-pancreas transplant; viral blip.

PubMed Disclaimer

References

REFERENCES

    1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601-2614. http://doi.org/10.1056/NEJMra064928.
    1. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89(7):779-795. http://doi.org/10.1097/TP.0b013e3181cee42f.
    1. Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis. 2011;52(3):313-321. http://doi.org/10.1093/cid/ciq143.
    1. Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13512. http://doi.org/10.1111/ctr.13512.
    1. Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13(s4):93-106. http://doi.org/10.1111/ajt.12103.

LinkOut - more resources